1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 3:Pre-HCT Lund-Mackay scores versus posttransplantation sinus outcomes
No. (Frequency) Pre-HCT Lund-Mackay Score (Mean) P Value All at screening 100 (100%) 3.48 ± 4.58 No post-HCT symptoms 79 (79%) 3.38 ± 4.49 .47 Post-HCT symptoms 21 (21%) 3.86 ± 5.00 Post-HCT symptoms, IFRS 2 (9.5%) 4.00 ± 4.24 .58 Post-HCT symptoms, no IFRS 19 (90.5%) 3.84 ± 5.17